Arbutus Biopharma (ABUS) Misses Q1 EPS by 3c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.76 million versus the consensus estimate of $1.77 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ross Stores, Inc. (ROST) PT Raised to $239 at UBS on Q2 Earnings Beat
• Albemarle names Max Hood as chief accounting officer